Levin Capital Strategies’s Revance Therapeutics, Inc. RVNC Stock Holding History

Levin Capital Strategies’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,000	Closed	-$277K	–	340
2018 Q1	$277K	Buy	+9,000	New	+$290K	0.01%	239
2016 Q1	–	Sell	-32,511	Closed	-$1.11M	–	373
2015 Q4	$1.11M	Sell	32,511 -11,333	-26%	-$393K	0.02%	192
2015 Q3	$1.3M	Sell	43,844 -31,417	-42%	-$954K	0.02%	181
2015 Q2	$2.41M	Sell	75,261 -17,078	-18%	-$439K	0.04%	156
2015 Q1	$1.91M	Buy	92,339 +4,355	+5%	+$75.2K	0.03%	175
2014 Q4	$1.49M	Buy	87,984 +5,329	+6%	+$93.1K	0.02%	182
2014 Q3	$1.6M	Sell	82,655 -102,111	-55%	-$2.66M	0.02%	182
2014 Q2	$6.28M	Buy	184,766 +137,812	+294%	+$4.32M	0.1%	129
2014 Q1	$1.48M	Buy	+46,954	New	+$1.47M	0.02%	190

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Levin Capital Strategies's RVNC Position: Q2 2018 in Review

Levin Capital Strategies sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2018, closing a stake of 9,000 shares — an estimated $277K sold.

Levin Capital Strategies first reported a position in RVNC in Q1 2014 and held it in 9 quarters. The position peaked at $6.28M in Q2 2014. 110 funds tracked by Wall St. Rank hold RVNC as of Q2 2018.

Levin Capital Strategies reported no remaining Revance Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Levin Capital Strategies sold 9,000 Revance Therapeutics, Inc. shares in Q2 2018, an estimated $277K.
Levin Capital Strategies first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 9 quarters.
Levin Capital Strategies's Revance Therapeutics, Inc. position peaked at $6.28M in Q2 2014.
110 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2018.

Based on Levin Capital Strategies's 13F filing for Q2 2018, filed 7 Aug 2018.